Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis
Status:
Unknown status
Trial end date:
2019-12-20
Target enrollment:
Participant gender:
Summary
Radiation therapy is one of the treatments for Nasopharyngeal carcinoma . The most common
side effects of post-radiation may be radiation-induced oral mucositis . When severe, oral
mucositis increases the risk of infection and may affect clinical outcomes due to treatment
interruption, dose reduction, and reduced treatment compliance. In China, a quadruple mixture
of dexamethasone, gentamicin, vitamin B12, and lidocaine is commonly used in patients who
begin to have radiation-induced oral mucositis . However, the incidence of radiation-induced
oral mucositis remains high. Recombinant bovine basic fibroblast growth factor is a
multifunctional cell growth factor that stimulates the growth of cells derived from mesoderm
and neuroectodermal cells and thus has a wide range of biological activities. The drug has
different degrees of promotion on the three stages of the wound repair process, namely the
local inflammatory reaction stage, cell proliferation and differentiation, granulation tissue
formation stage and tissue reconstruction stage. The purpose of this randomized controlled
trial was to evaluate the efficacy of recombinant bovine basic fibroblast growth factor as an
intervention in radiation-induced oral mucositis for the treatment of nasopharyngeal
carcinoma , with a commonly used quadruple mixture (from dexamethasone, gentamicin , vitamin
B12 and lidocaine composition) were compared.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Nanchang University
Treatments:
BB 1101 Dexamethasone Dexamethasone acetate Gentamicins Hydroxocobalamin Lidocaine Mitogens Vitamin B 12 Vitamin B Complex Vitamins